Cargando…

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain

OBJECTIVE: To conduct a cost-effectiveness analysis from the perspective of the Spanish National Health System (NHS) comparing ixekizumab versus secukinumab. DESIGN: A Markov model with a lifetime horizon and monthly cycles was developed based on the York model. Four health states were included: a b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schweikert, Bernd, Malmberg, Chiara, Núñez, Mercedes, Dilla, Tatiana, Sapin, Christophe, Hartz, Susanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Rheumatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430486/ https://www.ncbi.nlm.nih.gov/pubmed/32792421 http://dx.doi.org/10.1136/bmjopen-2019-032552

Ejemplares similares

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
por: Johansson, Erin, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK
por: Schweikert, Bernd, et al.
Publicado: (2020)

The Efficacy and Safety of Subcutaneous Ixekizumab for the Treatment of Axial Spondylarthritis: A Systematic Review and Meta-Analysis
por: Alzahrani, Ziyad, et al.
Publicado: (2023)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial
por: Brunner, Hermine I, et al.
Publicado: (2023)

Comorbidities in Patients with Psoriatic Arthritis
por: Haddad, Amir, et al.
Publicado: (2017)

Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis
por: Cai, Lin, et al.
Publicado: (2021)

Pseudoseptic Arthritis: An Initial Presentation of Underlying Psoriatic Arthritis
por: Paul, Prodip, et al.
Publicado: (2021)

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Kirkham, Bruce W., et al.
Publicado: (2023)

Clinical and ultrasonographic predictors for achieving minimal disease activity in patients with psoriatic arthritis: the UPSTREAM (Ultrasound in PSoriatic arthritis TREAtMent) prospective observational study protocol
por: Canzoni, Marco, et al.
Publicado: (2018)

Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Elewski, Boni E., et al.
Publicado: (2022)

Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
por: Lockshin, Benjamin, et al.
Publicado: (2022)

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

SLE and Serum Complement: Causative, Concomitant or Coincidental?
por: Sandhu, Vaneet, et al.
Publicado: (2018)

Effects of bDMARDs on quality of life in patients with psoriatic arthritis: meta-analysis
por: Lu, Yuqiong, et al.
Publicado: (2022)

Successful secukinumab treatment of erythrodermic psoriasis and psoriatic arthritis concomitant with severe noninfectious uveitis: a case report
por: Lu, Jiajing, et al.
Publicado: (2020)

Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study
por: Joven, Beatriz, et al.
Publicado: (2023)

T cell epitope mapping of secukinumab and ixekizumab in healthy donors
por: Spindeldreher, Sebastian, et al.
Publicado: (2020)

Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis
por: Ooms, Alexander, et al.
Publicado: (2023)

Concomitant Granulomatosis with Polyangiitis and C3 Glomerulonephritis Causing Renal Failure
por: Chaudhuri, Aadel A, et al.
Publicado: (2016)

Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population
por: Berman, Julia, et al.
Publicado: (2021)

Experiences and perceptions of patients with psoriatic arthritis participating in a trial of faecal microbiota transplantation: a nested qualitative study
por: Kragsnaes, Maja Skov, et al.
Publicado: (2021)

Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate
por: Poddubnyy, Denis, et al.
Publicado: (2020)

Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: protocol for a prospective, exploratory cohort study
por: Højgaard, Pil, et al.
Publicado: (2016)

Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry
por: Rahman, Proton, et al.
Publicado: (2020)

Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study
por: Rotar, Ziga, et al.
Publicado: (2020)

Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
por: Gisondi, Paolo, et al.
Publicado: (2014)

Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
por: Spindeldreher, Sebastian, et al.
Publicado: (2018)

Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry
por: Rahman, Proton, et al.
Publicado: (2017)

Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial
por: Kragsnaes, Maja Skov, et al.
Publicado: (2018)

Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: an observational cohort study in the Swiss Clinical Quality Management cohort
por: Vallejo-Yagüe, Enriqueta, et al.
Publicado: (2022)

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Ren, Vicky, et al.
Publicado: (2013)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Sekhon, Sahil, et al.
Publicado: (2017)

Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Blauvelt, Andrew, et al.
Publicado: (2023)

Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany
por: Krüger, Klaus, et al.
Publicado: (2018)

TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA)
por: Kleinrensink, Nienke J, et al.
Publicado: (2022)

Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial
por: Reich, Kristian, et al.
Publicado: (2022)

Long-term outcomes after coronary artery bypass surgery in patients with rheumatoid arthritis
por: Malmberg, Markus, et al.
Publicado: (2021)

Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab
por: Herrero-Moyano, María, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0ep8rre50kmrioejb32e51jb8c